|Dr. John M. Leonard||Pres & CEO||464.73k||N/A||1957|
|Mr. Nessan Bermingham Ph.D.||Founder & Member of Scientific Advisor Board||675.72k||N/A||1973|
|Ms. Rachel Haurwitz Ph.D.||Co-Founder||N/A||N/A||1986|
|Mr. José E. Rivera J.D., Esq.||Exec. VP of Operations and Gen. Counsel||564.39k||N/A||1966|
|Mr. Andrew May Ph.D.||Founder and Member of Scientific Advisor Board||N/A||N/A||N/A|
Intellia Therapeutics, Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; and partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics, Inc. has collaboration agreement with Novartis Institutes for BioMedical Research, Inc.; Regeneron Pharmaceuticals, Inc.; and Caribou Biosciences, Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Intellia Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2018 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.